As per reports, Merck & Co., Inc. (MRK) and partner Ridgeback Biotherapeutics have entered an agreement with the United Nations Children’s Fund (UNICEF) to supply up to 3 million courses of their COVID-19 antiviral pill.
Merck would supply the pill, molnupiravir, to UNICEF through the first half of 2022 for distribution in more than 100 low- and middle-income countries upon regulatory authorizations. The pill which is reported to be effective against the highly contagious Omicron variant received authorization from the U.S. Food and Drug Administration in December and has also been authorized in several other countries including Mexico, India, and the UK.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
